Abstracts Archive - Page 2359 of 2425 - ACR Meeting Abstracts

Abstract Number: 943 • 2012 ACR/ARHP Annual Meeting
Impact of Systemic Lupus Erythematosus On Work Productivity and Income in the United States
Alan Oglesby¹, Ellen Sulcs², Siva Narayanan³, Mechele Lee² and Cindy Garris⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Healthcare Research, Harris Interactive Inc., Rochester, NY, ³Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ⁴US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disorder characterized by fluctuating periods of disease activity affecting multiple organ systems. This study was…
Abstract Number: 944 • 2012 ACR/ARHP Annual Meeting
Job-Related Burden and Effort-Reward Imbalance in Patients with Systemic Lupus Erythematosus
Jutta G. Richter¹, Thomas Muth², Ralph Brinks¹, Tobias Koch³, Johannes Siegrist⁴, Nicole Hoffmann¹, Peter Angerer² and Matthias Schneider¹, ¹Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Medical Sociology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Working life factors influence patients’ (life) satisfaction and well being. Effort at work is part of a social contract that reciprocates effort by adequate…
Abstract Number: 945 • 2012 ACR/ARHP Annual Meeting
Work Loss in Systemic Lupus Erythematosus, the General Public, and Other Chronic Conditions
S. Sam Lim¹, Greg Dennis², Hong Kan³, Priti M. Jhingran³, Charles T. Molta⁴, Gaobin Bao⁵ and Cristina Drenkard⁶, ¹Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴GlaxoSmithKline, Philadelphia, PA, ⁵Medicine, Emory University, Atlanta, GA, ⁶Medicine, Div Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly develops in young groups, when many are establishing themselves in the workforce and can have a devastating impact on…
Abstract Number: 946 • 2012 ACR/ARHP Annual Meeting
Self-Reported Disease Activity and Health-Related Quality of Life in a Longitudinal Cohort of Patients with Systemic Lupus Erythematosus
Siva Narayanan¹, Ellen Sulcs², Alan Oglesby³, Cindy Garris⁴ and Mechele Lee², ¹Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ²Healthcare Research, Harris Interactive Inc., Rochester, NY, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, multisystem autoimmune disease with variable clinical manifestations and an unpredictable waxing and waning disease course impacting patient…
Abstract Number: 947 • 2012 ACR/ARHP Annual Meeting
The Impact of Dyspigmentation and Scarring in Cutaneous Lupus On Quality of Life
Saroj M. Verma¹, Joyce Okawa², Kathleen Propert³ and Victoria P. Werth⁴, ¹Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Patients with more severe cutaneous lupus activity have poorer quality of life. The main objective of the current study was to evaluate the impact…
Abstract Number: 948 • 2012 ACR/ARHP Annual Meeting
Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing
Ryo Rokutanda¹, Mitsumasa Kishimoto¹, Yasuharu Tokuda², Ken-ichi Yamaguchi¹, Hisanori Shimizu¹, Yasuhiro Suyama¹, Yuri Ohara¹, Yoichiro Haji¹, Chisun Min¹, Akira Takeda¹, Yukio Matsui³ and Masato Okada¹, ¹Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3…
Abstract Number: 949 • 2012 ACR/ARHP Annual Meeting
The Inverse Association Between Obesity and Anti-Nuclear Antibodies Is Modified by Systemic Inflammation and Maybe Associated with Body Composition
Irene Blanco¹, Monalyn Labitigan¹ and Matthew Abramowitz², ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Nephrology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Obesity and abdominal adiposity have been frequently associated with inflammation. However, an association of obesity with a decreased likelihood of anti-nuclear antibodies (ANAs) was…
Abstract Number: 950 • 2012 ACR/ARHP Annual Meeting
Performance of Various Anti-Nuclear Antibody Methodologies in the Assessment of Autoimmune Connective Tissue Diseases
Xiaoli Deng¹, Cynthia S. Crowson², Helen Khun², Melissa R. Snyder³ and Kevin G. Moder⁴, ¹Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose : The anti-nuclear antibody (ANA) is the classic biomarker associated with autoimmune connective tissue diseases (CTDs). ANA testing is often ordered as part of…
Abstract Number: 951 • 2012 ACR/ARHP Annual Meeting
A Systematic Review of Quality of Prognosis Studies in Systemic Lupus Erythematosus
Lily Siok Hoon Lim¹, Senq-J Lee², Brian M. Feldman³, D. D. Gladman⁴, Eleanor Pullenayegum⁵ and Earl D. Silverman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Pediatric Rheumatology Collaborative Study Group (PRSCG), Toronto, ON, Canada
Background/Purpose: Prognosis studies study future outcomes and/or seek to identify predictive or associative factors associated with outcomes. Strong and consistent prognostic factors can be used…
Abstract Number: 952 • 2012 ACR/ARHP Annual Meeting
Cognitive Behavioral Therapy and Milnacipran in Combination Appears to Be More Efficacious Than Either Therapy Alone
Dennis C. Ang¹, Mark P. Jensen², Jennifer L. Steiner³, Janna Hilligoss¹, Richard Gracely⁴ and Chandan Saha⁵, ¹Indiana University, Indianapolis, IN, ²Rehabilitation, University of Washington, Seattle, WA, ³Psychology, Indiana University Purdue University Indianapolis, Indianapolis, IN, ⁴Dentistry, University of North Carolina, Chapel Hill, NC, ⁵Biostatistics, Indiana University
Background/Purpose: The two treatment options that have received the significant attention in fibromyalgia (FM) management are cognitive behavioral therapy (CBT) and medications. Given the fact…
Abstract Number: 953 • 2012 ACR/ARHP Annual Meeting
Comparative Symptom Severity of Patients Satisfying Chronic Widespread Pain and Fibromyalgia Criteria
Frederick Wolfe¹, Brian Wallitt², Robert S. Katz³ and Winfried Häuser⁴, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Washington Hospital Center, Baltimore, MD, ³Rush University Medical Center, Chicago, IL, ⁴Klinikum Saarbrücken, Saarbrücken, Germany
Background/Purpose: Chronic widespread pain (CWP) is often used as a surrogate for fibromyalgia in epidemiological research, particularly in Europe and in whiplash-related injuries. This CWP…
Abstract Number: 914 • 2012 ACR/ARHP Annual Meeting
Prognosis for the Year 2030: The Consultation Prevalence of Osteoarthritis in Sweden May Increase by 50%
Aleksandra Turkiewicz¹, Ingemar F. Petersson², Jonas Björk³, Leif E. Dahlberg¹ and Martin Englund¹, ¹Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ²Lund University, Lund, Sweden, ³Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden, Lund, Sweden
Background/Purpose: To project the future prevalence of knee and hip osteoarthritis (OA) leading to doctor consultation. Methods: The Skåne Health Care Register is a legislative,…
Abstract Number: 915 • 2012 ACR/ARHP Annual Meeting
Incidence of Knee, Hip, and Hand Clinical Osteoarthritis: A Population-Based Cohort Study
Daniel Prieto-Alhambra¹, Aina Pagès-Castellà², M. Kassim Javaid³, Andrew Judge⁴, Cyrus Cooper⁵, Nigel K. Arden⁶ and Adolfo Díez-Pérez⁷, ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Barcelona, Spain, ³Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁴Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁵NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁶NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁷Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain
TITLE: "Incidence of knee, hip, and hand clinical osteoarthritis: a population-based cohort study."AUTHORS: Daniel Prieto-Alhambra*, Aina Pag�s-Castellˆ, M Kassim Javaid, Andrew Judge, Cyrus Cooper, Nigel…
Abstract Number: 916 • 2012 ACR/ARHP Annual Meeting
Population Incidence of Soft Tissue Knee Injury: Estimates From a Swedish Health Care Register
Charlotte Bergknut¹, George Peat², Richard Frobell³ and Martin Englund⁴, ¹Department of Orthopedics, Lund University, Lund, Sweden, ²Arthritis Research UK Primary Care Centre, Keele University, United Kingdom, ³Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Sweden, Sweden
Background/Purpose: Soft tissue knee injury is a well-established and potent risk factor for development of knee osteoarthritis. However, there is a paucity of epidemiological data…
Abstract Number: 917 • 2012 ACR/ARHP Annual Meeting
Feasibility of Remote Activity and Functional Status Monitoring of Patients with Hip or Knee Pain
Pim Jetanalin¹, Hyeon Eui Kim¹, Zia Agha², Nathaniel Heintzman¹, Lucila Ohno-Macado¹ and Susan J. Lee³, ¹University of California, San Diego, La Jolla, CA, ²San Diego Veterans Affairs Medical Center, San Diego, CA, ³University of California San Diego, La Jolla, CA
Background/Purpose: The incidence of total hip and knee arthroplasties has risen over the past decade and by 2030, the demand of these arthroplasties is estimated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].